The stock of PAVmed Inc (PAVM) has seen a 27.42% increase in the past week, with a 21.73% gain in the past month, and a -29.46% decrease in the past quarter. The volatility ratio for the week is 17.69%, and the volatility levels for the past 30 days are at 9.76% for PAVM. The simple moving average for the past 20 days is 20.18% for PAVM’s stock, with a -25.16% simple moving average for the past 200 days.
Is It Worth Investing in PAVmed Inc (NASDAQ: PAVM) Right Now?
Additionally, the 36-month beta value for PAVM is 1.23. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for PAVM is 9.73M and currently, short sellers hold a 3.64% ratio of that float. The average trading volume of PAVM on February 17, 2025 was 195.69K shares.
PAVM) stock’s latest price update
PAVmed Inc (NASDAQ: PAVM) has experienced a rise in its stock price by 19.88 compared to its previous closing price of 0.66. However, the company has seen a gain of 27.42% in its stock price over the last five trading days. prnewswire.com reported 2025-02-06 that NEW YORK, Feb. 6, 2025 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held February 11-12 at the Cliff Lodge in Snowbird, UT. Shaun O’Neil, Lucid’s President and Chief Operating Officer, will host one-on-one meetings throughout the conference.
Analysts’ Opinion of PAVM
Many brokerage firms have already submitted their reports for PAVM stocks, with Cantor Fitzgerald repeating the rating for PAVM by listing it as a “Overweight.” The predicted price for PAVM in the upcoming period, according to Cantor Fitzgerald is $8 based on the research report published on March 30, 2021 of the previous year 2021.
Ascendiant Capital Markets, on the other hand, stated in their research note that they expect to see PAVM reach a price target of $5. The rating they have provided for PAVM stocks is “Buy” according to the report published on November 05th, 2020.
Maxim Group gave a rating of “Buy” to PAVM, setting the target price at $5 in the report published on June 28th of the previous year.
PAVM Trading at 13.43% from the 50-Day Moving Average
After a stumble in the market that brought PAVM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.43% of loss for the given period.
Volatility was left at 9.76%, however, over the last 30 days, the volatility rate increased by 17.69%, as shares surge +22.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.83% lower at present.
During the last 5 trading sessions, PAVM rose by +27.42%, which changed the moving average for the period of 200-days by -53.80% in comparison to the 20-day moving average, which settled at $0.6573. In addition, PAVmed Inc saw 25.90% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PAVM starting from JAMES L. COX, who proposed sale 9,469 shares at the price of $0.78 back on Dec 12 ’24. After this action, JAMES L. COX now owns shares of PAVmed Inc, valued at $7,380 using the latest closing price.
JAMES L. COX, the Director of PAVmed Inc, proposed sale 38,095 shares at $0.86 during a trade that took place back on Dec 09 ’24, which means that JAMES L. COX is holding shares at $32,739 based on the most recent closing price.
Stock Fundamentals for PAVM
Current profitability levels for the company are sitting at:
- -13.8 for the present operating margin
- -0.99 for the gross margin
The net margin for PAVmed Inc stands at 6.03. The total capital return value is set at 7.95.
Based on PAVmed Inc (PAVM), the company’s capital structure generated 1.16 points at debt to capital in total, while cash flow to debt ratio is standing at -1.3. The debt to equity ratio resting at -7.17. The interest coverage ratio of the stock is -960.02.
Currently, EBITDA for the company is -75.74 million with net debt to EBITDA at 2.9. When we switch over and look at the enterprise to sales, we see a ratio of 10.64. The receivables turnover for the company is 252.12for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.06.
Conclusion
In conclusion, PAVmed Inc (PAVM) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
